HUP0400840A2 - Kis molekulatömegű hialuronsav immunogén készítményei, és eljárások A. csoportbeli és C. csoportbeli Streptococcusok által okozott fertőzések és betegségek megelőzéséhez, kezeléséhez és diagnózisához - Google Patents

Kis molekulatömegű hialuronsav immunogén készítményei, és eljárások A. csoportbeli és C. csoportbeli Streptococcusok által okozott fertőzések és betegségek megelőzéséhez, kezeléséhez és diagnózisához

Info

Publication number
HUP0400840A2
HUP0400840A2 HU0400840A HUP0400840A HUP0400840A2 HU P0400840 A2 HUP0400840 A2 HU P0400840A2 HU 0400840 A HU0400840 A HU 0400840A HU P0400840 A HUP0400840 A HU P0400840A HU P0400840 A2 HUP0400840 A2 HU P0400840A2
Authority
HU
Hungary
Prior art keywords
group
hyaluronic acid
weight hyaluronic
methods
streptococcus
Prior art date
Application number
HU0400840A
Other languages
English (en)
Inventor
Milan Blake
Maryline Laude-Sharp
Francis Michon
Samuel Moore
Original Assignee
Baxter Healthcare S.A.
Baxter International Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare S.A., Baxter International Inc. filed Critical Baxter Healthcare S.A.
Publication of HUP0400840A2 publication Critical patent/HUP0400840A2/hu
Publication of HUP0400840A3 publication Critical patent/HUP0400840A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

A találmány antigén kompozíciókat és eljárásokat nyújt A. csoportbeliés C. csoportbeli Streptococcusok által okozott fertőzések ésbetegségek kezeléséhez és megelőzéséhez. A találmány elsősorban kismolekulatömegű hialuronsavat, egy hordozóhoz kapcsolt kismolekulatömegű hialuronsavat, továbbá ezeket tartalmazó készítményeketbiztosít. A készítmények antitesteket váltanak ki kis molekulatömegűhialuronsavra, amely antitestek kereszt-reaktívak A. csoportbeli és C.csoportbeli Streptococcusokkal, és amelyeknek viszont csak minimáliskereszt-reaktivitásuk van natív hialuronsavval. A találmány különösenalkalmas mind aktív, mind passzív immunogén védelem nyújtására olyanegyedek számára, akik fertőzöttek A. csoportbeli vagy C. csoportbeliStreptococcusokkal, vagy ilyen fertőzés kockázatának vannak kitéve.Ezen kívül a találmány eljárásokat és készítményeket biztosít, amelyekalkalmasak az A. csoportbeli és C. csoportbeli Streptococcusok általokozott fertőzések és betegségek diagnosztizálására. Ó
HU0400840A 2001-05-11 2002-05-10 Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group a and group c streptococci HUP0400840A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/853,367 US20020192205A1 (en) 2001-05-11 2001-05-11 Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group A and group C streptococci
PCT/EP2002/005310 WO2002092131A2 (en) 2001-05-11 2002-05-10 Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins

Publications (2)

Publication Number Publication Date
HUP0400840A2 true HUP0400840A2 (hu) 2004-07-28
HUP0400840A3 HUP0400840A3 (en) 2004-10-28

Family

ID=25315838

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400840A HUP0400840A3 (en) 2001-05-11 2002-05-10 Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group a and group c streptococci

Country Status (15)

Country Link
US (1) US20020192205A1 (hu)
EP (1) EP1385554A2 (hu)
JP (1) JP2005508854A (hu)
KR (1) KR20030096369A (hu)
CN (1) CN1525869A (hu)
AR (1) AR034331A1 (hu)
BR (1) BR0209562A (hu)
CA (1) CA2446555A1 (hu)
CO (1) CO5550467A2 (hu)
EC (1) ECSP034888A (hu)
HU (1) HUP0400840A3 (hu)
MX (1) MXPA03010283A (hu)
PL (1) PL366692A1 (hu)
SK (1) SK15122003A3 (hu)
WO (1) WO2002092131A2 (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2251699C1 (ru) * 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
JP4576583B2 (ja) * 2005-03-22 2010-11-10 キユーピー株式会社 ヒアルロン酸またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物
US20070225484A1 (en) * 2006-03-25 2007-09-27 Framroze Bomi P Process for the Isolation and Stabilization of Low-Molecular Weight Aminoglycans from Waste Egg Shells
US8529951B1 (en) 2007-02-21 2013-09-10 Anand Ramamurthi Elastogenic cues and methods for using same
US9925209B2 (en) 2008-03-19 2018-03-27 The Board Of Regents Of The University Of Oklahoma Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same
US9687559B2 (en) 2008-03-19 2017-06-27 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
EP2341941A4 (en) * 2008-09-09 2014-12-10 Univ Oklahoma HEPAROSANE POLYMERS AND METHODS OF MAKING AND USING THEM TO ENHANCE THERAPEUTIC COMPOUNDS
PT2349520T (pt) * 2008-10-27 2016-08-16 Glaxosmithkline Biologicals Sa Método de purificação para hidrato de carbono de estreptococos grupo a
CN102010469B (zh) * 2010-10-22 2013-02-27 上海贝西生物科技有限公司 一种抗透明质酸单克隆抗体及其用途
EP2813515B1 (en) * 2012-02-07 2019-07-10 PHI Biomed Co., Ltd. Transdermally delivered hyaluronic acid-protein conjugate
CN104237500B (zh) * 2014-09-30 2016-09-28 博奥赛斯（天津）生物科技有限公司 一种透明质酸固相包被方法
TWI839327B (zh) * 2017-03-22 2024-04-21 美商建南德克公司 用於治療眼部病症之最佳化之抗體組合物
IT201900022626A1 (it) 2019-12-02 2021-06-02 Ub Care S R L Metodo per la determinazione del contenuto di sodio ialuronato in un idrogel
CN115590774B (zh) * 2022-10-20 2024-05-03 珠海原妙医学科技股份有限公司 透明质酸脂质体组装体及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
JPH0912600A (ja) * 1995-06-22 1997-01-14 Shiseido Co Ltd ヒアルロン酸ナトリウムに対するモノクローナル抗体及びその製造方法
JP2001510169A (ja) * 1997-07-17 2001-07-31 ノース アメリカン ワクチン， インコーポレイテッド Ｂ型髄膜炎菌性ポーリンおよびＨ．ｉｎｆｌｕｅｎｚａｅ多糖体を含む免疫原性結合体
WO1999062546A1 (en) * 1998-06-01 1999-12-09 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants

Also Published As

Publication number Publication date
US20020192205A1 (en) 2002-12-19
ECSP034888A (es) 2004-05-28
CA2446555A1 (en) 2002-11-21
WO2002092131A2 (en) 2002-11-21
HUP0400840A3 (en) 2004-10-28
JP2005508854A (ja) 2005-04-07
AR034331A1 (es) 2004-02-18
PL366692A1 (en) 2005-02-07
CO5550467A2 (es) 2005-08-31
BR0209562A (pt) 2004-03-30
CN1525869A (zh) 2004-09-01
KR20030096369A (ko) 2003-12-24
MXPA03010283A (es) 2004-12-06
SK15122003A3 (sk) 2004-10-05
WO2002092131A3 (en) 2003-03-20
EP1385554A2 (en) 2004-02-04

Similar Documents

Publication Publication Date Title
WO2021226436A8 (en) Optimized nucleotide sequences encoding sars-cov-2 antigens
HUP0400840A2 (hu) Kis molekulatömegű hialuronsav immunogén készítményei, és eljárások A. csoportbeli és C. csoportbeli Streptococcusok által okozott fertőzések és betegségek megelőzéséhez, kezeléséhez és diagnózisához
EA200400448A1 (ru) Применение стафилококковых и энтерококковых вакцин для защиты иммунокомпромиссного субъекта от бактериальных инфекций
ECSP044933A (es) Método y montaje para aumentar el volumen del cabello
HUP0002224A1 (hu) Virusellenes hatású benzimidazol-származékok
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
DE60041753D1 (de) Arzneimittel zur behandlung von c. pneumoniae infektionen
HUP0302636A2 (hu) Hasított burkolt víruskészítmény
IL199366A (en) An antibody containing hcdr3 sequence, an encoded amino acid sequence and a therapeutic, prophylactic or diagnostic preparation containing it
WO2002036790A3 (en) Influenza virus vector for infection of dendritic cells
SA521430813B1 (ar) لقاح وحدات فرعية لعلاج عدوى الجهاز التنفسي أو الوقاية منها
MX2020008454A (es) Composicion inmunogenica que comprende antigenos estafilococicos.
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
DE69732709D1 (de) Expressionsblockierung von virulenten faktoren in s. aureus
WO2000058475A3 (en) Streptococcus pneumoniae antigens
WO2002034773A3 (en) Streptococcal genes
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
HUP0101749A2 (hu) Készítmények PEG-interferon-alfa-konjugátumok védelmére és eljárás ilyen készítmények előállítására
WO2001040473A3 (en) Pseudomonas aeruginosa antigens
WO2022011271A3 (en) Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
WO2021257695A3 (en) Methods and compositions related to neutralizing antibodies against human coronavirus
WO2000063386A3 (en) Prevention, diagnosis and treatment of lyme disease
MX2023005221A (es) Composiciones inmunogenicas para uso en vacunas neumococicas.
MX2022008036A (es) Nuevo uso de formulacion inmunogenica bcg que expresa una proteina de virus respiratorio sincicial contra hmpv.
FR2868318B1 (fr) Antigene tat stabilise et ses applications pour la vaccination anti-vih